ArticleApplied health economics and health policy2023
A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany.
Article in Applied health economics and health policy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of catheter-directed thrombolysis on the socio-economic burden of pulmonary embolism in Germany: a cost-effectiveness analysis.European heart journal. Quality of care & clinical outcomes · 2026Pooled it
- Cost-effectiveness of integrative oncology for sustainable and patient-centred cancer care: a systematic review in the context of the WHO global traditional medicine strategy 2025-2034.Frontiers in public health · 2026Pooled it
- The cost of drug repurposing: parallel economic evaluation of mirtazapine for severe breathlessness in the multinational BETTER-B trial.BMC health services research · 2025Trial
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.PharmacoEconomics · 2026Article
- The Efficiency of the German Healthcare System: Some Puzzling Findings.The International journal of health planning and management · 2026Article
- Willingness to pay for a quality adjusted life year across different time horizons: direct elicitation in Quebec.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- The cost-effectiveness of inventory reserves for preventing drug shortages in Germany: a health-economic evaluation.Scientific reports · 2026Article
- Exploring the Generalizability of Foreign Cost-Effectiveness Analysis to Spain Using Data From a Scoping Review of Multinational Studies.PharmacoEconomics · 2026Article
- Cost-utility analysis of home treatment versus inpatient treatment in child and adolescent psychiatry: a decision analysis.Frontiers in child and adolescent psychiatry · 2026Article
- Evaluating the impact of the EU Medical Device Regulation (MDR) on mortality and device availability in Germany.PloS one · 2026Article
- Cost-Effectiveness of Positron Emission Tomography/Computed Tomography (PET/CT) in the Initial N-Staging of Head-Neck Cancer and Comparison with CT and Magnetic Resonance Imaging (MRI).Current oncology (Toronto, Ont.) · 2025Article
- Cost-utility analysis ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Article
- Value-based pricing of cognitive behavioral therapy for depression in primary care: an economic evaluation.BMC health services research · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeValue-based pricing of new, innovative health technologies defined as pricing through economic evaluation requires the use of a basic cost-effectiveness threshold. This study presents a cost-effectiveness model that determines the cost-effectiveness threshold for life-extending new, innovative technologies based on health system opportunity costs.
methodsTo estimate health system opportunity costs, the study used German data and examined the period between 1896 and 2014. To this end, it determined intertemporal differences in the remaining lifetime spending and life expectancy by age and gender. To account for the age composition of the population, it weighted age-specific intertemporal changes in the remaining lifetime spending and life expectancy by the age-specific population size. To estimate life expectancy gains solely attributable to the health care system, it used aggregated data on amenable mortality. It calculated the cost-effectiveness ratio of health care spending in the German health care system on average and at the margin.
resultsBased on the cost-effectiveness ratio of health care spending at the margin, the threshold value for life-prolonging new, innovative technologies was at least €42,634 per life-year gained, with a point estimate of €88,107 per life-year gained. Based on the average ratio, the threshold value dropped below €34,000 per life-year gained.
conclusionThis study provides new evidence on the cost-effectiveness threshold for value-based pricing of new, innovative technologies. Data from Germany suggest that a threshold value based on health care spending at the margin is considerably higher than that based on the average ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.